Trial Profile
Clinical study of adenocarcinoma with apatinib mesylate tablets combined with chemotherapy as second-line treatment of advanced gastric cancer or gastric esophagus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Apr 2019
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Fluorouracil; Irinotecan; Taxanes
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 16 Apr 2019 Primary endpoint (OS) has been met as per results published in the Journal of International Medical Research.
- 16 Apr 2019 Results published in the Journal of International Medical Research
- 16 Apr 2019 Status changed from not yet recruiting to completed as per results published in the Journal of International Medical Research